InnoCan Pharma Corp. operates as a pharmaceutical tech company. The firm focuses on the development of several drug delivery platforms combining cannabidiol (“CBD”) with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals. It operates through the following segments: the research and development of CBD loaded exosomes (“CLX”), the research and development of the use of CBD loaded liposomes and the commercialization and sale of branded CBD integrated pharmaceutical and topical treatment products. The company was founded in October2017 and is headquartered in Herzliya, Israel.
CSE
